CA2455439C - Dispositif visible sous un faisceau d'imagerie - Google Patents
Dispositif visible sous un faisceau d'imagerie Download PDFInfo
- Publication number
- CA2455439C CA2455439C CA2455439A CA2455439A CA2455439C CA 2455439 C CA2455439 C CA 2455439C CA 2455439 A CA2455439 A CA 2455439A CA 2455439 A CA2455439 A CA 2455439A CA 2455439 C CA2455439 C CA 2455439C
- Authority
- CA
- Canada
- Prior art keywords
- stent
- imaging beam
- density
- density enhancing
- opacifier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000003384 imaging method Methods 0.000 title claims description 42
- 239000000463 material Substances 0.000 claims abstract description 51
- 239000003814 drug Substances 0.000 claims description 20
- 230000002708 enhancing effect Effects 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 18
- 208000037803 restenosis Diseases 0.000 claims description 13
- 239000011248 coating agent Substances 0.000 claims description 12
- 238000000576 coating method Methods 0.000 claims description 12
- 239000003605 opacifier Substances 0.000 claims description 11
- 229920000642 polymer Polymers 0.000 claims description 10
- 238000003780 insertion Methods 0.000 claims description 8
- 230000037431 insertion Effects 0.000 claims description 8
- 238000012800 visualization Methods 0.000 claims description 8
- 239000002872 contrast media Substances 0.000 claims description 7
- 230000003628 erosive effect Effects 0.000 claims description 6
- 229910001026 inconel Inorganic materials 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 239000004033 plastic Substances 0.000 claims description 5
- 229920003023 plastic Polymers 0.000 claims description 5
- 229920000049 Carbon (fiber) Polymers 0.000 claims description 3
- 239000004917 carbon fiber Substances 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 3
- 239000002131 composite material Substances 0.000 claims description 3
- 238000006731 degradation reaction Methods 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 238000009792 diffusion process Methods 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 3
- 229910001220 stainless steel Inorganic materials 0.000 claims description 3
- 239000010935 stainless steel Substances 0.000 claims description 3
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 2
- 229910052788 barium Inorganic materials 0.000 claims description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims description 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 229920001600 hydrophobic polymer Polymers 0.000 claims description 2
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 claims description 2
- 229910001000 nickel titanium Inorganic materials 0.000 claims description 2
- 229910052715 tantalum Inorganic materials 0.000 claims description 2
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 claims description 2
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 claims description 2
- 229910052721 tungsten Inorganic materials 0.000 claims description 2
- 239000010937 tungsten Substances 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims 8
- 239000011247 coating layer Substances 0.000 claims 4
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 238000013170 computed tomography imaging Methods 0.000 abstract 1
- 238000002591 computed tomography Methods 0.000 description 23
- 238000000034 method Methods 0.000 description 15
- YXTWADZIBGVHPZ-UHFFFAOYSA-N 2-chloro-n-(2-chloroethyl)-n-[(5-methylthiophen-2-yl)methyl]ethanamine;hydrochloride Chemical compound Cl.CC1=CC=C(CN(CCCl)CCCl)S1 YXTWADZIBGVHPZ-UHFFFAOYSA-N 0.000 description 13
- 230000002792 vascular Effects 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 10
- 238000012545 processing Methods 0.000 description 10
- 210000001367 artery Anatomy 0.000 description 9
- 238000010968 computed tomography angiography Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 7
- 230000002980 postoperative effect Effects 0.000 description 7
- 238000002583 angiography Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 206010002329 Aneurysm Diseases 0.000 description 5
- 208000031481 Pathologic Constriction Diseases 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 230000036262 stenosis Effects 0.000 description 4
- 208000037804 stenosis Diseases 0.000 description 4
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 229920002988 biodegradable polymer Polymers 0.000 description 3
- 239000004621 biodegradable polymer Substances 0.000 description 3
- 210000001715 carotid artery Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- UNEIHNMKASENIG-UHFFFAOYSA-N para-chlorophenylpiperazine Chemical compound C1=CC(Cl)=CC=C1N1CCNCC1 UNEIHNMKASENIG-UHFFFAOYSA-N 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010061876 Obstruction Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 206010057469 Vascular stenosis Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000003073 embolic effect Effects 0.000 description 2
- 238000002594 fluoroscopy Methods 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 201000000054 Coronary Restenosis Diseases 0.000 description 1
- 206010056489 Coronary artery restenosis Diseases 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 241000201776 Steno Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000002302 brachial artery Anatomy 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 210000000275 circle of willis Anatomy 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011982 device technology Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- -1 p-carboxyphenoxy Chemical group 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229940020573 plavix Drugs 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Abstract
L'invention présente un implant fait d'un matériau fonctionnel pour réaliser les fonctions thérapeutiques attendues d'un implant et aussi fait d'un matériau ayant une radio-opacité qui préserve de manière substantielle l'apparence de l'implant lorsque l'implant est vu sous un faisceau d'imagerie de tomographie. Un tel implant permet un suivi de l'implant et des vaisseaux sanguins l'entourant sur un tomodensitogramme.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2455439A CA2455439C (fr) | 2003-03-24 | 2004-01-20 | Dispositif visible sous un faisceau d'imagerie |
| PCT/US2004/040443 WO2005055806A2 (fr) | 2003-12-05 | 2004-12-06 | Dispositif visible sous un faisceau imageur |
| EP04812874.8A EP1691721B1 (fr) | 2003-12-05 | 2004-12-06 | Dispositif visible sous un faisceau imageur |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2423735 CA2423735A1 (fr) | 2002-03-25 | 2003-03-24 | Dispositif observable sous un faisceau d'imagerie |
| CA2,423,735 | 2003-03-24 | ||
| US10/394,007 | 2003-03-24 | ||
| US10/394,007 US20030204248A1 (en) | 2002-03-25 | 2003-03-24 | Device viewable under an imaging beam |
| US10/727,667 US7927368B2 (en) | 2002-03-25 | 2003-12-05 | Device viewable under an imaging beam |
| US10/727,667 | 2003-12-05 | ||
| CA2455439A CA2455439C (fr) | 2003-03-24 | 2004-01-20 | Dispositif visible sous un faisceau d'imagerie |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2455439A1 CA2455439A1 (fr) | 2004-09-24 |
| CA2455439C true CA2455439C (fr) | 2014-02-11 |
Family
ID=32996069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2455439A Expired - Lifetime CA2455439C (fr) | 2003-03-24 | 2004-01-20 | Dispositif visible sous un faisceau d'imagerie |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2455439C (fr) |
-
2004
- 2004-01-20 CA CA2455439A patent/CA2455439C/fr not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2455439A1 (fr) | 2004-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9028543B2 (en) | Device viewable under an imaging beam | |
| EP1649829A1 (fr) | System de pose de stent auto-expansible, comprenent un catheter a ballonnet | |
| Eggebrecht et al. | Nonsurgical retrieval of embolized coronary stents | |
| US20030204248A1 (en) | Device viewable under an imaging beam | |
| Sakai et al. | Descending thoracic aortic aneurysm: thoracic CT findings after endovascular stent-graft placement | |
| Karaman et al. | Endovascular stent graft treatment in a patient with splenic artery aneurysm | |
| Neri et al. | Spiral CT virtual endoscopy of abdominal arteries: clinical applications | |
| Truijers et al. | Endovascular aneurysm repair: state-of-art imaging techniques for preoperative planning and surveillance | |
| EP1691721B1 (fr) | Dispositif visible sous un faisceau imageur | |
| CA2455439C (fr) | Dispositif visible sous un faisceau d'imagerie | |
| van den Berg et al. | Three-dimensional rotational angiography in peripheral endovascular interventions | |
| Priestley et al. | Iatrogenic vertebral arteriovenous fistula treated with a hemobahn stent-graft | |
| Peynircioglu et al. | Stent-graft applications in peripheral non-atherosclerotic arterial lesions | |
| RU2216273C1 (ru) | Способ выявления стеноза висцеральных и почечных артерий при тромбированных аневризмах брюшной аорты | |
| Laspas et al. | Imaging of coronary artery bypass grafts by computed tomography coronary angiography | |
| US20220296249A1 (en) | Endovascular coil device for embolization of blood vessels | |
| Carlsson | Imaging in vascular surgery | |
| Abdelaziz et al. | Role of color Doppler ultrasound for assessment of arteriovenous fistula dysfunction in hemodialysis patients | |
| Kpodonu | Manual of thoracic endoaortic surgery | |
| Duvnjak | Endovascular Treatment of Arterial Emergencies | |
| Tsoumakidou et al. | Detection of complications after aortic stent grafting | |
| Rubin et al. | MDCT angiography of the thoracic aorta | |
| Gullipalli et al. | Use of Duplex Ultrasound Imaging Post-Endovascular Aneurysm Repair (EVAR) A Pictorial Review | |
| Carlsson et al. | Imaging in vascular surgery | |
| Song | Multidector CT imaging of coronary artery stent and coronary artery bypass graft |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20240122 |